AML
From the Journals
Adverse cytogenetics trump molecular risk in NPM1-mutated AML
The findings have implications for postremission treatment decisions, including whether NPM1-mutated patients should receive allogeneic...
From the Journals
Genetic analysis highlights value of germline variants in MDS, AML
Systematic genetic testing for DDX41 mutations may aid in clinical decision making for adults with MDS or AML.
From the Journals
Nonmyeloablative conditioning carries lowers infection risk in patients with AML
Patients who received myeloablative conditioning tended to develop infections sooner.
From the Journals
How to recognize pediatric leukemia cutis
The most common type of leukemia associated with leukemia cutis was acute myeloid leukemia.
Conference Coverage
ADMIRAL results solidify gilteritinib as new standard for FLT3-mutated AML
AMSTERDAM – Patients treated with gilteritinib has superior overall survival, compared with four salvage chemotherapy regimens.
Conference Coverage
Guadecitabine offers limited advantage over other standards for high-risk AML
AMSTERDAM – In order to see this limited advantage with guadecitabine, patients had to undergo at least four cycles of treatment.
Conference Coverage
Risk model could help predict VTE in acute leukemia
AMSTERDAM – VTE risk modeling is available for patients with solid tumors, but a similar prognostic tool for leukemia patients has been missing....
Conference Coverage
AML variants before transplant signal need for aggressive therapy
AMSTERDAM – Patients who had genomic evidence of a lingering AML variant had worse posttransplant outcomes when they underwent reduced-intensity...
Conference Coverage
For tough AML, half respond to selinexor plus chemotherapy
AMSTERDAM – The addition of selinexor looks promising in relapsed/refractory AML, but Karyopharm Therapeutics will be focusing first on approval...
Conference Coverage
Antibody targeting ‘do not eat me’ signals is active in AML, MDS
CHICAGO – 5F9 plus azacitidine eradicated leukemia stem cells in responding patients, providing a mechanism for potential long-term durability.
Conference Coverage
Combo produces ‘best response rate’ after first relapse in kids with AML
CHICAGO – CPX-351 followed by fludarabine, cytarabine, and filgrastim produced an overall response rate of 81%.